M&A Deal Summary |
|
|---|---|
| Date | 2015-10-14 |
| Target | Zalicus Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Taro Pharmaceuticals |
| Sellers(s) | Epirus Biopharmaceuticals |
| Deal Type | Divestiture |
| Deal Value | 4M USD |
SEARCH BY
Taro Pharmaceuticals, Inc. is a pharmaceutical company.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: British Columbia M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
| Employees | 73 |
Epirus Biopharmaceuticals is a biopharmaceutical company, develops, manufactures and commercializes biosimilar therapeutics worldwide. Epirus Biopharmaceuticals is based in Boston, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: British Columbia M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-09-09 |
Bioceros BV
Utrecht, Netherlands Bioceros BV is a biopharmaceutical R&D company focused on the development of mAbs and generation of GMP-ready cell lines. Over the past decade, Bioceros has developed numerous biosimilar cell lines from its proprietary, well-characterized CHO platform (CHOBC®)i. |
Buy | $14M |
